This invention generally relates to a composition and method of using recombinant microRNAs (miRNA) and their hairpin-like precursors (pre-miRNA) as therapeutic drugs for treating Alzheimer’s diseases (AD). More specifically, the present invention relates to the use of man-made miRNA miR-302 precursors (pre-miR-302) for AD therapy in humans. These pre-miR-302 molecules can be mass produced in prokaryotes as a form of DNA expression-competent DNA vectors and/or hairpin-like RNAs. As prokaryotic cells do not transcribe or process hairpin-like RNAs, the present invention also teaches a method for expressing pre-miRNAs in prokaryotes, i.e. pro-miRNA, using a novel hairpin-like RNA transcription mechanism newly found in prokaryotes. Additionally, since miR-302 is a well-known embryonic stem cell (ESC)-specific factor in humans, our novel findings of this invention can be further used to advance the designs and development of novel regenerative medicine for treating many other ageing-related degenerative diseases, such as Parkinson’s diseases, osteoporosis, diabetes, and cancers.本發明一般涉及使用重組microRNA(miRNA)及其髮夾型前驅物(pre-miRNA)作為用於治療阿茲海默症(AD)的治療藥物之組合物及方法。更具體而言，本發明涉及人工製造之miRNA miR-302前驅物(pre-miR-302)在人類的阿茲海默症治療中的用途。這些pre-miR-302分子可在原核生物中以DNA表達勝任DNA載體及/或髮夾型RNA之形式大量生成。由於原核細胞不會轉錄或處理髮夾型RNA，本發明亦教示一種用於在原核生物中使用在原核生物中新發現之新穎髮夾型RNA轉錄機制來表達pre-miRNAs的方法，亦即，pro-miRNA。此外，由於miR-302是人類眾所周知的胚胎幹細胞(ESC)特異性因子，本新穎發明之研究結果可進一步推廣用於治療許多其他老化相關退行性疾病之新穎再生醫學的設計及開發，例如帕金森氏症、骨質疏鬆症、糖尿病及癌症。
